ClinicalTrials.gg
CompletedNCT03573518Updated Apr 18, 2022Results posted

Evaluation of BTX 1503 in Patients With Moderate to Severe Acne Vulgaris

A Phase 2 interventional study of BTX 1503 and Vehicle in Acne Vulgaris, sponsored by Botanix Pharmaceuticals. Completed at 36 sites in 2 countries. Open to participants aged 12 Years to 40 Years. Per ClinicalTrials.gov, last updated 2022-04-18.

Sponsored by Botanix Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
368
Allocation
Randomized
Ages
12 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 373 studies in Acne Vulgaris with a site in United States — 20 open to participants now, 29 under way, 2 of them phase 3. Acne Vulgaris · United States.

Enrollment
95th of 353
368 · median 78
Started
2018
with 19 others
Phase 2
65 of 373
none open now
Registered
253rd of 373
by date

Among the 373 studies in Acne Vulgaris with a site in United States, this one is the 95th largest by enrollment of the 353 interventional ones that give a count, is one of 20 that started in 2018, is one of 65 in phase 2, and was the 253rd registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

20 of the 373 studies in Acne Vulgaris with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 12 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 373 studies in Acne Vulgaris with a site in United States, or all of them as a file.
02

Study summary

The objective of this study is to assess safety and efficacy of various doses of BTX 1503 liquid formulation in subjects with moderate to severe acne vulgaris of the face.

Read the detailed description

This will be a multi-center, randomized, double-blinded, vehicle-controlled, parallel group, dose-finding study in pediatrics, adolescents and adults (aged 12 to 40 years). The objective of this study is to assess the safety and efficacy of various doses of BTX 1503 in subjects with moderate to severe acne vulgaris of the face.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

Keywords

  • Synthetic CBD
  • Cannabidiol
04

Who can participate

Ages eligible
12 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject (or legal guardian) has the ability and willingness to sign a written /assent.
  2. Subject is of either gender and 12 to 40 years of age.
  3. Subject is in good general health without haematological, cardiac, respiratory, renal, endocrine, gastrointestinal, psychiatric, hepatic, or malignant disease, as determined by the investigator.
  4. Subject has suitable venous access for blood sampling.
  5. Subject is able and willing to complete the study and to comply with all study instructions and attend the necessary visits.
  6. Subject has acne vulgaris of the face defined as:

    1. 20 to 50 (inclusive) inflammatory lesions on the face
    2. 20 to 100 (inclusive) non-inflammatory lesions on the face
    3. An Investigator's Global Assessment (IGA) score for acne severity of 3 or 4 (moderate or severe) assessed on the face.
  7. Subject has ≤ 2 nodular/cystic acne lesions (>5 mm in diameter).
  8. Subject must refrain from the use of other treatments for acne during the study.
  9. Subject must agree to not wash or shave their face, swim or otherwise get their face wet for at least 1 hour after application of study medication.
  10. Subject must agree to maintain their regular use of sunscreens, moisturizers, shaving cream, and facial make up throughout the entire course of the study.
  11. Male subjects and their partners must agree and commit to use a barrier method of during the study and for 90 days after last study drug application.
  12. A negative UPT result for all at the Screening Visit and Baseline Visit, if applicable. A WOCBP is one who is not permanently sterilized or is not . Postmenopausal is defined as 24 months with no menses without an alternative medical cause.
  13. Sexually active women must agree to use the following throughout the study and for 30 days after last study drug application:

    a. One of these highly effective contraception methods i. Intrauterine device (IUD); hormonal (injections, implants, transdermal patch, vaginal ring; tubal ligation; partner vasectomy, OR b. Oral contraceptives WITH a barrier method (listed below), OR c. Two barrier forms of contraception (listed below) i. Male or female condom; diaphragm; cervical cap.

  14. Male subjects must refrain from sperm donation during the study treatment period until 90 days after final study drug administration.
  15. Male subjects must agree to keep their face clean shaven (no moustache or goatee; short sideburns acceptable) throughout the study and use the same method for shaving as was used for the 4 weeks prior to the Screening Visit.

Exclusion criteria

Exclusion Criteria:

  1. People who would otherwise qualify for the study but are living in the same household as a study subject, are not allowed to participate in the study.
  2. Female subject who is breast feeding, pregnant, or planning to become pregnant any time during the course of the study.
  3. Subject with history of known or suspected intolerance to the drug product .
  4. Subject has known infection.
  5. Subject has acne conglobata, acne fulminans, secondary acne (chloracne), pseudo-folliculitis, severe acne requiring systemic treatment, or is taking a medication known to induce or exacerbate acne.
  6. Subject has severe truncal acne.
  7. Subject has excessive facial hair that would interfere with the evaluation of safety or with the diagnosis or assessment of acne vulgaris.
  8. Subject has sunburns, unevenness in skin tones, tattoos, scars, excessive hair, freckles, birthmarks, moles, or other skin damage or abnormality that would result in the inability to evaluate the skin of the face.
  9. Subject has any skin condition of the face other than acne vulgaris.
  10. Subject has used oral retinoid (e.g. isotretinoin) within 6 months (180 days) prior to the Baseline Visit.
  11. Subject has used Vitamin A supplements greater than 10,000 units/day within 6 months (180 days) prior to the Baseline Visit.
  12. Subject has used androgen receptor blockers (such as spironolactone or flutamide) within 3 months (90 days) prior to the Baseline Visit.
  13. Subject has initiated treatment with hormonal therapy or changed dosing with hormonal therapy within 3 months (90 days) prior to the Baseline Visit.
  14. Subject has had facial procedures (chemical or laser peel, microdermabrasion, etc.) within 8 weeks (56 days) prior to the Baseline Visit.
  15. Subject has had treatment with systemic antibiotics within 4 weeks (28 days) prior to the Baseline Visit.
  16. Subject has had treatment with systemic anti-acne drugs within 4 weeks (28 days) prior to the Baseline Visit.
  17. Subject has had treatment with systemic anti-inflammatory drugs within 4 weeks (28 days) prior to the Baseline Visit.
  18. Subject has had treatment with systemic (oral) other medications within 4 weeks (28 days) prior to the Baseline Visit.
  19. Subject has had treatment with prescription topical retinoid use on the face (e.g. tretinoin, tazarotene) within 4 weeks (28 days) prior to the Baseline Visit.
  20. Subject has had treatment with topical prescription antibiotics (e.g. dapsone, clindamycin, erythromycin, or sulfacetamide) or combination products that include a topical antibiotic within 2 weeks (14 days) prior to the Baseline Visit.
  21. Subject has had treatment with over-the-counter (OTC) topical medications for the treatment of acne vulgaris including benzoyl peroxide, topical anti- inflammatory medications, corticosteroids, adapalene, α-hydroxy/glycolic acid on the face within 2 weeks (14 days) prior to the Baseline Visit.
  22. Subject is currently using any medication that, in the opinion of the investigator, may affect the evaluation of the study product or place the subject at undue risk.
  23. Subject has had photodynamic therapy within 8 weeks (56 days) prior to the Baseline Visit.
  24. Subject has used a tanning bed within 2 weeks (14 days) prior to the Baseline Visit.
  25. Subject has used home-based light treatment within 2 weeks (14 days) prior to the Baseline Visit.
  26. Subject has an underlying disease that requires the use of interfering topical or systemic therapy.
  27. Subject has other dermatological conditions that require the use of interfering topical or systemic therapy or that might interfere with study assessments such as, but not limited to, atopic dermatitis, psoriasis, perioral dermatitis, or rosacea.
  28. Subject has had excessive sun exposure (in the opinion of the investigator) within one week prior to the Baseline Visit and an unwillingness to refrain from excessive sun exposure during the study.
  29. Subject has a history or currently suffering from any disease or condition that, in the opinion of the investigator, may affect the evaluation of the study product or place the subject at undue risk. This may include respiratory (including chronic asthma requiring repetitive drug interventions), gastrointestinal, renal, hepatic, hematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, or connective tissue diseases or disorders.
  30. Subject has a clinically relevant history of, or current evidence of, abuse of alcohol or other drugs. Subjects may be deemed eligible if the UDS identifies subject-reported, prescribed drugs or appropriate levels of alcohol, as determined by the investigator.
  31. Subject has participated in another drug or device research study within 4 weeks (28 days) of the Baseline Visit or five half-lives of the drug, whichever is longer.
  32. Any other reason that would make the subject, in the opinion of the investigator or sponsor, unsuitable for the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
368 participants (actual)

Study arms

  • Experimental
    BTX 1503 5% BID

    BTX 1503 5% CBD (w/w) solution twice daily

    Drug: BTX 1503

  • Experimental
    BTX 1503 5% QD

    BTX 1503 5% CBD (w/w) solution once daily

    Drug: BTX 1503

  • Experimental
    BTX 1503 2.5% QD

    BTX 1503 2.5% CBD (w/w) solution once daily

    Drug: BTX 1503

  • Placebo comparator
    Vehicle BID

    Vehicle twice daily

    Drug: Vehicle

  • Placebo comparator
    Vehicle QD

    Vehicle once daily

    Drug: Vehicle

Interventions

  • BTX 1503 Dose 1 liquid formulation, or BTX 1503 Dose 2 liquid formulation

    Also known as: BTX1503

  • DrugVehicle

    Placebo

06

What researchers measure

Primary outcomes

  1. Safety as Measured by Reported Adverse Events

    Summary of Treatment-Emergent Adverse Events by MedDra Preferred Term that Occurred with a Frequency \> 2% in any Treatment Group (Safety Population)

    Time frame: Day 84

Secondary outcomes

  1. Absolute Change From Baseline in Inflammatory Lesion Counts

    Summary of Absolute Change from Baseline in Inflammatory Count at Day 84 (Intent-to-Treat Population)

    Time frame: Day 84

07

Results

Posted Apr 18, 2022

Participant flow

Participant flow — Overall Study
MilestoneBTX 1503 5% BIDBTX 1503 5% QDBTX 1503 2.5% QDVehicle Combined (BID or QID)
Started92929292
Completed69777081
Not completed23152211

Outcome measures

PrimarySafety as Measured by Reported Adverse Events

Summary of Treatment-Emergent Adverse Events by MedDra Preferred Term that Occurred with a Frequency \> 2% in any Treatment Group (Safety Population)

Time frame:
Day 84
Reported as:
Number · TEAEs
Safety as Measured by Reported Adverse Events
TEAEsBTX 1503 5% BIDBTX 1503 5% QDBTX 1503 2.5% QDVehicle Combined (BID or QID)
Upper Respiratory tract infection2455
Viral upper respiratory tract infection3234
Headache1120
Acne2020
Cough1020
Oropharyngeal pain0201
SecondaryAbsolute Change From Baseline in Inflammatory Lesion Counts

Summary of Absolute Change from Baseline in Inflammatory Count at Day 84 (Intent-to-Treat Population)

Time frame:
Day 84
Reported as:
Least squares mean · Lesions
Absolute Change From Baseline in Inflammatory Lesion Counts
LesionsBTX 1503 5% BIDBTX 1503 5% QDBTX 1503 2.5% QDVehicle Combined (BID or QID)
Absolute Change From Baseline in Inflammatory Lesion Counts-8.5 ± 12.57-12 ± 12.58-11.7 ± 12.57-11.3 ± 12.57

Adverse events

Collected over Approximately 3 months. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BTX 1503 5% BID0/92 (0%)0/92 (0%)9/92 (9.8%)
BTX 1503 5% QD0/91 (0%)0/91 (0%)9/91 (9.9%)
BTX 1503 2.5% QD0/91 (0%)0/91 (0%)14/91 (15.4%)
Vehicle Combined (BID or QID)0/91 (0%)0/91 (0%)10/91 (11%)
Most frequent other events
Most frequent other events
EventBTX 1503 5% BIDBTX 1503 5% QDBTX 1503 2.5% QDVehicle Combined (BID or QID)
Upper respiratory tract infectionRespiratory, thoracic and mediastinal disorders2/924/915/915/91
Viral upper respiratory tract infectionRespiratory, thoracic and mediastinal disorders3/922/913/914/91
HeadacheNervous system disorders1/921/912/910/91
AcneSkin and subcutaneous tissue disorders2/920/912/910/91
CoughRespiratory, thoracic and mediastinal disorders1/920/912/910/91
Oorpharyngeal PainGastrointestinal disorders0/922/910/911/91

Baseline characteristics

Age, Continuous
Age, Continuous(years)BTX 1503 5% BIDBTX 1503 5% QDBTX 1503 2.5% QDVehicle Combined (BID or QID)Total
Mean19.5 ± 6.6519.7 ± 5.9919.4 ± 5.9820.5 ± 6.1420.0 ± 6.17
Sex: Female, Male
Sex: Female, Male(Participants)BTX 1503 5% BIDBTX 1503 5% QDBTX 1503 2.5% QDVehicle Combined (BID or QID)Total
Female56605855229
Male36323437139
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BTX 1503 5% BIDBTX 1503 5% QDBTX 1503 2.5% QDVehicle Combined (BID or QID)Total
Hispanic or Latino2621232393
Not Hispanic or Latino66716969275
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BTX 1503 5% BIDBTX 1503 5% QDBTX 1503 2.5% QDVehicle Combined (BID or QID)Total
American Indian or Alaska Native01001
Asian555722
Native Hawaiian or Other Pacific Islander30115
Black or African American1255628
White67757372287
More than one race568625
Unknown or Not Reported00000
Inflammatory Lesion Count
Inflammatory Lesion Count(Lesions)BTX 1503 5% BIDBTX 1503 5% QDBTX 1503 2.5% QDVehicle Combined (BID or QID)Total
Mean29.3 ± 8.5228.5 ± 8.9529.6 ± 8.0029.1 ± 8.2529.1 ± 8.37
08

Study locations

36 sites
  • Applied Research Center of Arkansas
    Little Rock, Arkansas 72212, United States
  • Encino Research Center
    Encino, California 91436, United States
  • Dermatology Specialist, Inc.
    Murrieta, California 92562, United States
  • Quest Dermatology Research
    Northridge, California 91324, United States
  • Clinical Science Insitute
    Santa Monica, California 90404, United States
  • Well Phrama Medical Research
    Miami, Florida 33143, United States
  • Tory Sullivan, M.D., PA
    North Miami Beach, Florida 33162, United States
  • Precision Clinical Research
    Sunrise, Florida 33351, United States
  • DS Research - Louisville
    Louisville, Kentucky 40241, United States
  • Delricht Research
    New Orleans, Louisiana 70115, United States
  • Metro Boston Clinical
    Brighton, Maine 02135, United States
  • Minnesota Clinical Study Center
    Fridley, Minnesota 55432, United States
  • Medisearch Clinical Trials
    Saint Joseph, Missouri 64506, United States
  • Washington University School of Medicine - Dermatology
    Saint Louis, Missouri 63141, United States
  • JDR Dermatology Research
    Las Vegas, Nevada 89148, United States
  • The Acne Treatment and Research Center
    Morristown, New Jersey 07960, United States
  • Aventiv Research
    Dublin, Ohio 43016, United States
  • Penn State Hershey Medical
    Hershey, Pennsylvania 17033, United States
  • Clinical Partners, LLC
    Johnston, Rhode Island 02919, United States
  • Greenville Dermatology, LLC
    Greenville, South Carolina 29607, United States
  • Coastal Carolina Research Center
    Mount Pleasant, South Carolina 29464, United States
  • Avant Research Associates, LLC
    Austin, Texas 78704, United States
  • DermReasearch
    Austin, Texas 78759, United States
  • J&S Studies, Inc.
    College Station, Texas 77845, United States
  • Suzanne Bruce and Associates, PA
    Houston, Texas 77056, United States
  • Cmax Clinical Research
    Adelaide, 5000, Australia
  • The Skin Centre
    Benowa, 4217, Australia
  • Burswood Dermatology
    Burwood, 6100, Australia
  • Skin & Canver Foundation Inc.
    Carlton, 053, Australia
  • Sinclair Dermatology
    East Melbourne, 3002, Australia
  • Fremantle Dermatology
    Fremantle, 6160, Australia
  • North Eastern Health Specialist
    Hectorville, 5073, Australia
  • St George Dermatology & Skim Cancer Center
    Kogarah, 2217, Australia
  • Captain Sterline Medical Centre
    Nedlands, 6009, Australia
  • Woden Dermatology
    Phillip, 2606, Australia
  • Varacity Clinical Research
    Woolloongabba, 4102, Australia
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Aug 2019, 13 months.

Results were first posted in Apr 2022, 2 years 8 months after primary completion.

Of 29 industry-sponsored phase 2 interventional studies under Acne Vulgaris, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 13 months is above that.

Counting every sponsor, half of 37 studies reached it within 9 months; a quarter within 6 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2018
First posted
Jun 29, 2018
StartActual
Jun 26, 2018
Primary completionActual
Aug 16, 2019
CompletionActual
Sep 5, 2019
Results first posted
Apr 18, 2022
Last update
Apr 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03573518
Lead sponsor
Botanix Pharmaceuticals
Responsible party
Sponsor
First posted
Jun 29, 2018
Start date
Jun 26, 2018
Primary completion
Aug 16, 2019
Completion
Sep 5, 2019
Results posted
Apr 18, 2022
Last update
Apr 18, 2022

Study contacts

Anthony Robinson, CRNP
study director · Head of Development, Botanix Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabidiol

Start the discussion